SunTrust Banks Inc. reiterated their buy rating on shares of Tesaro Inc. (NASDAQ:TSRO) in a research report sent to investors on Wednesday. SunTrust Banks Inc. currently has a $91.60 price target on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. Mizuho boosted their price target on shares of Tesaro from $67.00 to $94.00 and gave the company a buy rating in a research note on Tuesday, July 5th. Citigroup Inc. boosted their price target on shares of Tesaro from $65.00 to $90.00 and gave the company a buy rating in a research note on Friday, July 1st. Wedbush reissued a buy rating on shares of Tesaro in a research note on Thursday, June 30th. FBR & Co reissued a buy rating on shares of Tesaro in a research note on Thursday, June 30th. Finally, Leerink Swann reissued a buy rating on shares of Tesaro in a research note on Monday, June 6th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Tesaro currently has an average rating of Buy and a consensus target price of $94.40.

Shares of Tesaro (NASDAQ:TSRO) opened at 104.11 on Wednesday. The firm’s market capitalization is $5.35 billion. The firm has a 50-day moving average of $91.68 and a 200 day moving average of $61.56. Tesaro has a 52 week low of $29.51 and a 52 week high of $104.48.

Tesaro (NASDAQ:TSRO) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.43. The business had revenue of $36.60 million for the quarter, compared to the consensus estimate of $4.98 million. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. During the same period in the previous year, the firm earned ($1.51) EPS. On average, equities research analysts expect that Tesaro will post ($7.33) EPS for the current fiscal year.

In other news, VP Jeffrey H. Hanke sold 12,500 shares of the company’s stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $74.35, for a total value of $929,375.00. Following the completion of the transaction, the vice president now owns 12,500 shares in the company, valued at approximately $929,375. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Edward C. English sold 7,000 shares of the company’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $88.54, for a total transaction of $619,780.00. Following the completion of the transaction, the vice president now owns 3,500 shares of the company’s stock, valued at approximately $309,890. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Fund Advisors boosted its position in shares of Tesaro by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,293,906 shares of the biopharmaceutical company’s stock valued at $56,971,000 after buying an additional 23,384 shares during the last quarter. BlackRock Inc. boosted its position in shares of Tesaro by 13.3% in the first quarter. BlackRock Inc. now owns 7,096 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 834 shares during the last quarter. venBio Select Advisor LLC bought a new position in shares of Tesaro during the first quarter valued at about $6,605,000. Pictet Asset Management Ltd. boosted its position in shares of Tesaro by 35.8% in the first quarter. Pictet Asset Management Ltd. now owns 55,000 shares of the biopharmaceutical company’s stock valued at $2,225,000 after buying an additional 14,500 shares during the last quarter. Finally, Emerald Acquisition Ltd. bought a new position in shares of Tesaro during the second quarter valued at about $23,685,000. Institutional investors and hedge funds own 88.87% of the company’s stock.

About Tesaro

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.